Prosecution Insights
Last updated: October 26, 2026
Application No. 17/877,664

COMPOSITIONS AND METHODS FOR ANALYSIS USING NUCLEIC ACID PROBES AND BLOCKING SEQUENCES

Non-Final OA §102§112
Filed
Jul 29, 2022
Priority
Jul 30, 2021 — provisional 63/227,824
Examiner
SALMON, KATHERINE D
Art Unit
1682
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
10x Genomics Inc.
OA Round
3 (Non-Final)
43%
Grant Probability
Moderate
3-4
OA Rounds
0m
Est. Remaining
81%
With Interview

Examiner Intelligence

Grants 43% of resolved cases
43%
Career Allowance Rate
342 granted / 798 resolved
-17.1% vs TC avg
Strong +38% interview lift
Without
With
+37.7%
Interview Lift
resolved cases with interview
Typical timeline
4y 0m
Avg Prosecution
72 currently pending
Career history
917
Total Applications
across all art units

Statute-Specific Performance

§101
19.5%
-20.5% vs TC avg
§103
28.1%
-11.9% vs TC avg
§102
11.3%
-28.7% vs TC avg
§112
35.2%
-4.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 798 resolved cases

Office Action

§102 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . It is noted that the Primary Examiner has changed. Please direct all future correspondences to Katherine Salmon. This action is in response to papers filed 6/11/2026. Claims 1,4,6,9,12,22,23,25,28,30,31,40,41,42,43,52,54,56,86,87 are pending. This action is nonfinal. Withdrawn Rejections The rejections made in the prior office action are withdrawn after consideration of the pre appeal conference. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1,4,6,9,12,22,23,25,28,30,31,40,41,42,43,52,54,56,86,87 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claims 1,4,6,9,12,22,23,25,28,30,31,40,41,42,43,52,54, 86,87 are indefinite over step a of claim 1. Step a requires providing a probe comprising an interrogatory region and a blocking strand. The wherein clause are drawn to differently hybridization methods, however, it is not clear if the step is requiring this hybridization or if the claim step only requires “providing”. Claim 56 is indefinite over step a of claim 56. Step a requires providing a probe comprising an interrogatory region and a blocking strand. The wherein clause are drawn to differently hybridization methods, however, it is not clear if the step is requiring this hybridization or if the claim step only requires “providing”. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 1,4,6,9,12,22,23,25,28,30,31,40,41,42,43,52,54,56,86,87 is/are rejected under 35 U.S.C. 102(a) as being anticipated by Soderberg et al. (US Patent Application 2017/0009278 Jan 12, 2017). With regard to claim 1, Soderberg et al. teaches a method detecting a region on interest (abstract). Soderberg et al. teaches providing a probe with an interrogatory region (para 133) and a blocking strand (para 29). Soderberg et al. teaches hybridization between a probe and target with a displaced region (para 27-30). Soderberg et al. teaches ligating and detecting an amplification product (para 244-247). With regard to claim 4, Soderberg et al. teaches that the blocking oligonucleotide can be within another molecule (para 27). With regard to claim 6, Soderberg et al. teaches that the blocking and probe can be in the same molecule (para 27). Soderberg et al. teaches that the probe is a circular probe comprising a specific stem loop structure with an region of interest and a stem that can be blocking (27-35). With regard to claim 9, Soderberg et al. teaches a probe is a circularizable probe and the ligating in step (c) circularizes the circularizable probe (para 41-56). With regard to claim 12, Soderberg et al. teaches rolling circle amplification (para 88). With regard to claim 22 and 25, Soderberg et al. teaches that the blocking sequence can be ribonucleotides at the end of the of the probe (para 29-33). With regard to claim 23 and 30, Soderberg et al. teaches that the interrogation can be within the probe (para 133). With regard to claim 28, Soderberg et al. teaches a mismatch (snp) (para 207-213). With regard to claim 31, Soderberg et al. teaches a method wherein the probe has a region adjacent to the region of interest for displacement (para 29-33). With regard to claim 40, Soderberg et al. a method of removing probe bound to mismatches before ligation (para 99-107). With regard to claim 41, Soderberg et al. teaches probes that have more mismatches are less stable (para 87-88). With regard to claims 42, Soderberg et al. teaches a removing step with multiple washes (para 181-186). With regard to claim 43, Soderberg et al. teaches methods of using RCA assays (para 88). With regard to claim 52, Soderberg et al. teaches a method wherein the RCA product has a barcode (para 88). With regard to claim 54, Soderberg et al. teaches detection of barcodes by contacting labeled probes with the barcodes and detecting the signals (para 88, 99-111). With regard to claim 56, Soderberg et al. teaches contacting the sample with a circular probe hybridized to a blocking strand (para 27-30). Hybridizing a toehold region of RNA molecules, the blocking strand is displaced and hybridizing a first target RNA and second target using RCA (para 27-100). With regard to claim 86, Soderberg et al. teaches that the clocking strand can hybridize to the hybridization region and block (para 190). With regard to claim 87, Soderberg et al. that the blocking strand hybridizes the region and blocks it from hybridizing to the probe (para 190). Conclusion No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to KATHERINE D SALMON whose telephone number is (571)272-3316. The examiner can normally be reached 9-530. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Wu Cheng (Winston) Shen can be reached at 5712723157. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /KATHERINE D SALMON/Primary Examiner, Art Unit 1682
Read full office action

Prosecution Timeline

Jul 29, 2022
Application Filed
Jul 29, 2025
Non-Final Rejection mailed — §102, §112
Oct 27, 2025
Response Filed
Mar 18, 2026
Final Rejection mailed — §102, §112
Jun 11, 2026
Response after Non-Final Action
Jun 11, 2026
Notice of Allowance
Jul 22, 2026
Response after Non-Final Action
Oct 05, 2026
Non-Final Rejection mailed — §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12767985
METHODS OF DIAGNOSING A DISEASE STATE
5y 4m to grant Granted Oct 20, 2026
Patent 12760366
METHODS FOR DETERMINING RESPONSIVENESS TO ANTI-TUMOR NECROSIS FACTOR THERAPY IN THE TREATMENT OF PSORIASIS
4y 6m to grant Granted Oct 13, 2026
Patent 12748103
METHODS FOR SELECTING AND TREATING CANCER WITH FGFR3 INHIBITORS
3y 9m to grant Granted Sep 29, 2026
Patent 12729405
METHOD AND KIT FOR DETERMINING BENEFIT OF CHEMOTHERAPY
4y 6m to grant Granted Sep 08, 2026
Patent 12709776
NOVEL MARKER OF EPITHELIAL-MESENCHYMAL TRANSITION IN PANCREATIC CANCER
4y 12m to grant Granted Aug 18, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
43%
Grant Probability
81%
With Interview (+37.7%)
4y 0m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 798 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month